[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced tha

Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovatio

First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resiste

Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated

Published prospective cohort showed durable responses and manageable safety in patients with HCC fol

First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal ca

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximate

A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has trig

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced new translational and clinic

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and c

Medical Affairs scale-up supports France's multi-tumor AAC access framework and expanding paid n

Agenus (NASDAQ:AGEN) reported quarterly earnings of $1.94 per share which missed the analyst consens

Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maint

Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combinat

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maint

Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the

Agenus (NASDAQ:AGEN) reported quarterly losses of $(1.00) per share which missed the analyst consens

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that four abstracts highligh

Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA)

Agenus Inc. (NASDAQ:AGEN) a leader in immuno-oncology innovation, today announced that its botensili

Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models

On June 3, 2025, Agenus Inc. (the "Company") and its wholly-owned subsidiary Agenus West, LL

Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO pr

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:AGEN) with a Neutral and raises the price tar

HC Wainwright & Co. analyst Emily Bodnar upgrades Agenus (NASDAQ:AGEN) from Neutral to Buy an

Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access

Agenus will also grant Zydus an exclusive license to develop and commercialize BOT and BAL in India

Presenting new data in the most mature readout to date, with 60% more patients and reported median a

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:AGEN) with a Neutral and raises the price tar

Agenus (NASDAQ:AGEN) reported quarterly losses of $(1.03) per share which beat the analyst consensus

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that data from the investiga

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:AGEN) with a Neutral and lowers the price tar

Key Operational Highlights:Achieved Q4 2024 operational cash burn of $28.7 million, substantially re